Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Ruxience (rituximab-pvvr)
i
Other names:
PF-05280586, PF 05280586, PF05280586
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Trials
Company:
Pfizer
Drug class:
CD20 inhibitor
Related drugs:
‹
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
F007 (rituximab biosimilar) (0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
rituximab (176)
obinutuzumab (68)
epcoritamab-bysp (11)
ofatumumab (8)
ublituximab-xiiy (7)
rituximab-abbs (6)
rituximab/hyaluronidase (5)
Rixathon (rituximab biosimilar) (4)
EX103 (3)
ibritumomab tiuxetan (3)
IMM0306 (2)
IGM-2323 (2)
mosunetuzumab-axgb (2)
AR160 (2)
rituximab-arrx (2)
glofitamab-gxbm (1)
TQB2303 (rituximab biosimilar) (1)
IPH6501 (1)
odronextamab (1)
Ritucad (rituximab biosimilar) (1)
ACE1831 (0)
AcellBia (rituximab biosimilar) (0)
ACTR087 (0)
ALETA-001 (0)
ripertamab (0)
zuberitamab (0)
Avetux (rituximab biosimilar) (0)
B001 (0)
BAT4306F (0)
obinutuzumab-β (0)
BI 695500 (rituximab biosimilar) (0)
BM-ca (0)
CHO-H01 (0)
CIMAbior (rituximab biosimilar) (0)
CND261 (0)
DI Leu16 IL-2 (0)
IGN002 (0)
(0)
GB241 (rituximab biosimilar) (0)
GSK5926371 (0)
Halpryza (rituximab biosimilar) (0)
Hanlikon (rituximab biosimilar) (0)
Reditux (rituximab biosimilar) (0)
JHL1101 (rituximab biosimilar) (0)
JMT601 (0)
JNJ-8543 (0)
JS203 (0)
Kikuzubam (rituximab biosimilar) (0)
FBTA05 (0)
MabionCD20 (rituximab biosimilar) (0)
Mabtas (rituximab biosimilar) (0)
MK-8808 (rituximab biosimilar) (0)
MT-3724 (0)
NAV-006 (0)
Novex (rituximab biosimilar) (0)
AME-133v (0)
ocrelizumab (0)
XmAb13676 (0)
PRO131921 (0)
PRO-203 (0)
PSB202 (0)
Retuxira (rituximab biosimilar) (0)
TG20 (rituximab biosimilar) (0)
SAIT101 (rituximab biosimilar) (0)
SIBP-02 (rituximab biosimilar) (0)
TQB2825 (0)
TRU-015 (0)
veltuzumab (0)
›
Associations
(6)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Diffuse Large B Cell Lymphoma
CD20 positive
Diffuse Large B Cell Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Chronic Lymphocytic Leukemia
CD20 positive
Chronic Lymphocytic Leukemia
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Follicular Lymphoma
CD20 positive
Follicular Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
CD20 positive
Non-Hodgkin’s Lymphoma
CD20 positive
Non-Hodgkin’s Lymphoma
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
rituximab-pvvr
Sensitive: A1 - Approval
rituximab-pvvr
Sensitive
:
A1
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.